A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed

Inclusion Criteria: * Healthy subjects aged 2months (60-89 days) and 3months (90-119 days) ； * Willing to provide proof of identity * Subjects aged 2 months have not been vaccinated with DTaP, IPV, Hib, or 13-valent pneumococcal polysaccharide conjugate vaccine; * Subjects of 3 months have not been inoculated with DTaP vaccine, and IPV (only group A3）； * Subjects'guardians or trustees are able to understand and sign the informed consent voluntarily, comply with the requirements of the clinical study plan. Exclusion Criteria: * With temperature \>37.0°C on axillary setting before vacciation; * With a medical history of diphtheria, pertussis or tetanus; * Had contact with individuals with confirmed pertussis, diphtheria and tetanus diseases in their families in the past 30 days; * Premature birth (delivery before the 37th week of pregnancy)or low birth weight (birth weight\< \<2500g); * History of dystocia, suffocation rescue, neurological damage; * With congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. * History of epilepsy, convulsions or convulsions, or have a family history of mental illness; * History of abnormal blood coagulation (such as coagulation factor deficiency, coagulopathy); * Had received immune enhancement or inhibitor therapy (continuous oral or instillation for more than 14 days); * History of severe allergic reactions to vaccination, such as difficulty breathing, urticaria; * Any prior administration of blood products in last 3 month; * Any prior administration of attenuated live vaccine in last 14 days; * Any prior administration of subunit or inactivated vaccines in last 7 days; * Plans to participate in or is participating in any other drug clinical study; * Has any other factors judged by investigators that make them unfit to participate in the clinical trial